2019The Egyptian Journal of Hospital MedicineOpen access

A prospective Study of the Risk of Depression in Acne Patients Treated with Oral Isotretinoin

Rabie Bedir Atallahb, Hany Othman Abo Al-Wafa, Mohamed Abdel Fattah El Mahdy, Asmaa Elsayed Mahmoud

Open full text 0 citations

Abstract

Background: depression showed up as potential side effect of isotretinoin in the summary of product characteristics. There have been numerous studies treating this issue yet as a rule not distinguishing any significant depression or suicide risk. Aim of the Work: this study aimedto evaluate the risk of depression in acne patients treated with oral isotretinoin therapy. Methods: one hundred patients with moderate to severe acne were enrolled in non-controlled prospective study. The psychological condition was evaluated at the baseline and fourth month by the Hamilton Depression Rating Scale (HDRS) for all patients. Statistical analysis of HDRS scores was performed. Results: all patients completed the study. Before the treatment 18% of the patients had suffered from mild depressive symptoms. at end of 4 months The patient's scores remained below the subclinical level for depression except only 2 patients one was mildly depressed turned to moderately depressed after four months treatment with isotretinoin other was mildly depressed and still mildly depressed after four months treatment with isotretinoin. The incidence of depression was 1%. Symptoms of depression which occurred in two patients, in which case coexisting situational factors were found to be the cause. Conclusion: our results showed that the oral isotretinoin treatment for acne at the typical therapeutic dose caused significant reduction in depression scores with a depression incidence only 1%. These changes might be related to clinical effect of isotretinoin. Moreover, the treatment of acne improved symptoms of depression for most patients.

Open-access reader

About this research paper

What this paper is about

Background: depression showed up as potential side effect of isotretinoin in the summary of product characteristics. There have been numerous studies treating this issue yet as a rule not distinguishing any significant depression or suicide risk. Aim of the Work: this study aimedto evaluate the risk of depression in acne patients treated with oral isotretinoin therapy. Methods: one hundred patients with moderate to severe acne were enrolled in non-controlled prospective study. The psychological condition was evaluated at the baseline and fourth month by the Hamilton Depression Rating Scale (HDRS) for all patients. Statistical analysis of HDRS scores was performed. Results: all patients completed the study. Before the treatment 18% of the patients had suffered from mild depressive symptoms. at end of 4 months The patient's scores remained below the subclinical level for depression except only 2 patients one was mildly depressed turned to moderately depressed after four months treatment with isotretinoin other was mildly depressed and still mildly depressed after four months treatment with isotretinoin. The incidence of depression was 1%. Symptoms of depression which occurred in two patients, in which case coexisting situational factors were found to be the cause. Conclusion: our results showed that the oral isotretinoin treatment for acne at the typical therapeutic dose caused significant reduction in depression scores with a depression incidence only 1%. These changes might be related to clinical effect of isotretinoin. Moreover, the treatment of acne improved symptoms of depression for most patients.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: depression showed up as potential side effect of isotretinoin in the summary of product characteristics. There have been numerous studies treating this issue yet as a rule not distinguishing any significant depression or suicide risk. Aim of the Work: this study aimedto evaluate the risk of depression in acne patients treated with oral isotretinoin therapy. Methods: one hundred patients with moderate to severe acne were enrolled in non-controlled prospective study. The psychological condition was evaluated at the baseline and fourth month by the Hamilton Depression Rating Scale (HDRS) for all patients. Statistical analysis of HDRS scores was performed. Results: all patients completed the study. Before the treatment 18% of the patients had suffered from mild depressive symptoms. at end of 4 months The patient's scores remained below the subclinical level for depression except only 2 patients one was mildly depressed turned to moderately depressed after four months treatment with isotretinoin other was mildly depressed and still mildly depressed after four months treatment with isotretinoin. The incidence of depression was 1%. Symptoms of depression which occurred in two patients, in which case coexisting situational factors were found to be the cause. Conclusion: our results showed that the oral isotretinoin treatment for acne at the typical therapeutic dose caused significant reduction in depression scores with a depression incidence only 1%. These changes might be related to clinical effect of isotretinoin. Moreover, the treatment of acne improved symptoms of depression for most patients.

Key concepts: Medicine, Acne, Isotretinoin, Depression (economics), Prospective cohort study, Dermatology, Internal medicine, Macroeconomics

Related papers

Back to paper searchBrowse research topicsOriginal source
A prospective Study of the Risk of Depression in Acne Patients Treated with Oral Isotretinoin — Research Paper | ScholarLens